Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Ryanair Holdings plc — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Ryanair Holdings plc trades at $51.99 (market cap $26.41B). The key difference: Ryanair Holdings plc is far larger — about 27.1× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Ryanair Holdings plc pays a 1.69% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Ryanair Holdings plc for 72 Days on average.
| MRVI | RYAAY | |
|---|---|---|
Market Cap | $972.90M | $26.41B |
Volume | 4,325,710 | 2,266,391 |
Sector | Health | Industrials |
52-Week High | $9.00 | $73.82 |
52-Week Low | $2.83 | $51.33 |
Typical Hold Time | 0 Days | 72 Days |
Enterprise Value | $1.08B | $23.47B |
Dividend Yield | — | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
RYAAY trades at $51.33, down 3.15% amid bearish technical signals despite strong fundamentals. The stock shows robust profitability with 12.13% net margins and attractive valuation at 13.23 P/E. Recent earnings performance has been mixed with Q1 2026 beating expectations but Q2 2026 missing. Technical indicators signal bearish momentum with oversold RSI conditions, while analyst consensus remains positive with 64.71% buy ratings.
The outlook balances strong operational performance against near-term headwinds including fuel cost volatility and Boeing MAX 10 certification delays. Revenue growth trajectory and market share gains support long-term potential, though elevated oil prices and competitive pressures present significant risks. Current valuation levels offer entry opportunity for patient investors despite technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
